^
Association details:
| Biomarker: | SRSF2 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2848 Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients
Published date:
11/02/2023
Excerpt:
CONTRADICTING EVIDENCE: Patients mutated for SRSF2 had a 4.8 months OS and a 5 months LFS compared to 11.3 and 8 months, respectively (p=0.034 and p=0.037)...SRSF2mut seems to be predictive of a worse survival in ND AML treated with VEN-AZA.
Secondary therapy:
azacitidine
Source:
Title:
CL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA
Published date:
05/11/2023
Excerpt:
...TP53 mutation (p=0.005) and complex karyotype (p=0.003) were the strongest predictors of venetoclax resistance, while IDH2 (p=0.006) and SRSF2 (p=0.007) mutations predicted favorable responses (FigureA).
Trial ID:
Source:
Title:
AZACITIDINE PLUS VENETOCLAX FOR THE TREATMENT OF RELAPSED AND FIRST-LINE AML PATIENTS
Published date:
05/12/2022
Excerpt:
This retrospective study included consecutive patients treated with VEN-AZA for R/R AML and ND AML....ASXL1, IDH1/2 and SRSF2 mutations were associated with a trend in a higher response rate in the R/R group.
Secondary therapy:
azacitidine
